Hims & Hers Health (HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will also include the official rollout of the telehealth company’s Hers platform. HIMS stock has rallied 65% year-to-date, driven by the demand for GLP-1 treatments, growth beyond weight-loss drugs into areas such as menopause support, and international expansion.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hims & Hers Health Launches Weight-Loss Plans in the UK
Hims & Hers’ weight-loss membership and treatment plans in the UK will include Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Mounjaro drugs. The company will also offer Orlos (generic name orlistat), an over-the-counter (OTC) weight-loss treatment.
It is worth noting that HIMS offers sexual health, skincare, and hair loss treatments for male customers in the UK. Also, in June 2025, the company announced its acquisition of London-based telemedicine platform Zava. Notably, the Zava deal expanded Hims & Hers Health’s footprint to Germany, France, and Ireland, with the company expecting expansion into additional markets.
Interestingly, both Novo Nordisk’s and Eli Lilly’s drugs cost far less in the UK than in the U.S., though access to them through the country’s National Health Service (NHS) has been limited. HIMS noted that access to GLP-1 treatment plans remains challenging on the NHS and through the private sector, owing to high demand and escalating costs.
Recently, HIMS reported mixed third-quarter results. While the company’s Q3 revenue grew 49% year-over-year to $599 million, earnings per share (EPS) of $0.06 lagged estimates amid margin pressures.
Is HIMS Stock a Buy, Sell, or Hold?
Currently, Wall Street has a Hold consensus rating on Hims & Hers Health stock based on six Holds, three Buys, and three Sells. The average HIMS stock price target of $47.63 indicates about 20% upside potential.
